Clinical Trial Update: A Study to Learn About the Vepdegestrant (ARV-471, PF-07850327) in People With ER+/HER2- Locally Advanced or Metastatic Breast Cancer (BC) [Phase 1]

View source ↗

Summary

Pfizer's Phase 1 study of Vepdegestrant (ARV-471) for ER+/HER2- locally advanced or metastatic breast cancer has posted results; the trial is currently active b…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Vepdegestrant (ARV-471)

Snippet

Sponsor: Pfizer | Conditions: Breast Neoplasms | Phase 1 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-09-23